Prognostic Significance and Treatment Response Associations of Genetic Mutations in Chronic Myelomonocytic Leukemia: A Retrospective Cohort Study
Open Access
- 28 October 2024
- journal article
- research article
- Published by MDPI AG in Biomedicines
- Vol. 12 (11) , 2476
Abstract
Background: This retrospective cohort study investigates the prognostic significance of genetic mutations in Chronic Myelomonocytic Leukemia (CMML) and their association with treatment responses among patients treated at a single institution, juxtaposed with a statewide dataset from Kentucky. Methods: The study includes 51 patients diagnosed with CMML under the World Health Organization criteria from January 2005 to December 2023. It examines their genomic profiles and subsequent survival outcomes. The analysis also categorizes patients into CMML-1 and CMML-2 subtypes and assesses survival differences between transformed and non-transformed cases. Results: Mutations in TET2, ASXL1, and SRSF2 were found to significantly influence survival, establishing their roles as critical prognostic markers. Additionally, the cohort from the University of Kentucky exhibited distinct survival patterns compared to the broader Kentucky state population, suggesting that demographic and treatment-related factors could underlie these variances. Conclusions: This research underscores the pivotal role of targeted genetic profiling in deciphering the progression of CMML and refining therapeutic strategies. The findings emphasize the necessity for advanced genetic screening in managing CMML to better understand individual prognoses and optimize treatment efficacy, thereby offering insights that could lead to personalized treatment approaches.Keywords
All Related Versions
Funding Information
- National Computational Infrastructure (P30 CA177558)
This publication has 17 references indexed in Scilit:
- Chronic myelomonocytic leukemia: 2024 update on diagnosis, risk stratification and managementAmerican Journal of Hematology, 2024
- Machine Learning Improves Risk Stratification in Myelodysplastic Neoplasms: An Analysis of the Spanish Group of Myelodysplastic SyndromesHemaSphere, 2023
- Proposals for Clinical Trials in Chronic Myelomonocytic LeukemiaCurrent Treatment Options in Oncology, 2023
- Impact of Mutational Status and Prognostic Factors on Survival in Chronic Myelomonocytic Leukemia With Systemic Inflammation and Autoimmune DisordersHemaSphere, 2023
- Impact of age on the cumulative risk of transformation in patients with chronic myelomonocytic leukaemiaEuropean Journal of Haematology, 2021
- Activity of venetoclax-based therapy in chronic myelomonocytic leukemiaLeukemia, 2021
- Outcomes of patients with chronic myelomonocytic leukaemia treated with non-curative therapies: a retrospective cohort studyThe Lancet Haematology, 2021
- Venetoclax/decitabine for a pediatric patient with chronic myelomonocytic leukemiaPediatric Blood & Cancer, 2020
- Suboptimal response rates to hypomethylating agent therapy in chronic myelomonocytic leukemia; a single institutional study of 121 patientsAmerican Journal of Hematology, 2019
- Hypomethylating agent therapy use and survival in older patients with chronic myelomonocytic leukemia in the United States: A large population‐based studyCancer, 2017